Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.
British Journal of Haematology|August 9, 2017
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Shaji Kumar, et al.
Blood Cancer Journal|May 13, 2020
"Direct to Drug" screening as a precision medicine tool in multiple myelomaCecilia Bonolo de Campos, Nathalie Meurice, Joachim L Petit, et al.
Annals of Hematology|April 4, 2018
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaJonas Paludo, Jithma P Abeykoon, Amanda Shreders, et al.
Blood|October 6, 2016
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomibShaji K Kumar, Betsy R LaPlant, Craig B Reeder, et al.
Mayo Clinic Proceedings|August 12, 2006
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMartha Q Lacy, Angela Dispenzieri, Morie A Gertz, et al.
Mayo Clinic Proceedings|August 8, 2015
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus StatementAngela Dispenzieri, Francis Buadi, Shaji K Kumar, et al.
Mayo Clinic Proceedings|March 15, 2017
Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted TherapyDavid Dingli, Sikander Ailawadhi, P Leif Bergsagel, et al.
Nature Medicine|November 15, 2016
IAP antagonists induce anti-tumor immunity in multiple myelomaMarta Chesi, Noweeda N Mirza, Victoria M Garbitt, et al.
Mayo Clinic Proceedings|April 2, 2013
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013Joseph R Mikhael, David Dingli, Vivek Roy, et al.
Pageof 6